Decheng Capital LLC reported 14 positions worth $731.75M for the quarter ended Jun 30, 2026, up 10.7% on the prior quarter. It opened 1 new position, added to 0, trimmed 3 and exited 1. Its largest holding is CG Oncology, Inc. at 61.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | +20.0K | – | $625.20K | 0.085% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | +20.0K | $625.20K | 0.085% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| KRYS Krystal Biotech, Inc. | -7,300 | $1.89M | 0.285% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CGON CG Oncology, Inc. | Healthcare | 6.37M | $452.71M | 61.87% | 0 | 0.0% | Unchanged | 7.22% |
| 2 | NUVB Nuvation Bio Inc. | Healthcare | 25.95M | $147.42M | 20.15% | 0 | 0.0% | Unchanged | 7.42% |
| 3 | AARD Aardvark Therapeutics, Inc. | Healthcare | 3.92M | $22.56M | 3.08% | 0 | 0.0% | Unchanged | 17.9% |
| 4 | ACRS Aclaris Therapeutics, Inc. | Healthcare | 4.04M | $21.38M | 2.92% | 0 | 0.0% | Unchanged | 2.83% |
| 5 | UPB Upstream Bio, Inc. | Healthcare | 2.72M | $18.86M | 2.58% | 0 | 0.0% | Unchanged | 4.98% |
| 6 | RCUS Arcus Biosciences, Inc. | Healthcare | 464.8K | $14.33M | 1.96% | -13.0K | -2.7% | Reduced | 0.37% |
| 7 | EQ Equillium, Inc. | Healthcare | 4.45M | $14.23M | 1.94% | 0 | 0.0% | Unchanged | 3.98% |
| 8 | RVMD Revolution Medicines, Inc. | Healthcare | 52.7K | $9.86M | 1.35% | -40.8K | -43.7% | Reduced | 0.02% |
| 9 | LYEL Lyell Immunopharma, Inc. | Healthcare | 692.1K | $9.72M | 1.33% | 0 | 0.0% | Unchanged | 2.96% |
| 10 | BYSI BeyondSpring Inc. | Healthcare | 3.80M | $6.65M | 0.909% | 0 | 0.0% | Unchanged | 9.24% |
| 11 | ZNTL Zentalis Pharmaceuticals, Inc. | Healthcare | 1.32M | $6.42M | 0.877% | 0 | 0.0% | Unchanged | 1.85% |
| 12 | NAMS NewAmsterdam Pharma Co N.V. | Healthcare | 176.9K | $5.99M | 0.819% | -148.2K | -45.6% | Reduced | 0.14% |
| 13 | PYXS Pyxis Oncology, Inc. | Healthcare | 326.8K | $983.70K | 0.134% | 0 | 0.0% | Unchanged | 0.51% |
| 14 | TNGX Tango Therapeutics, Inc. | Healthcare | 20.0K | $625.20K | 0.085% | +20.0K | – | New | 0.01% |
Tip. Select a row to see that position’s full history at Decheng Capital.
As of its Q2 2026 13F filing, Decheng Capital LLC’s five largest positions were CG Oncology, Inc. (CGON) at 61.9%, Nuvation Bio Inc. (NUVB) at 20.1%, Aardvark Therapeutics, Inc. (AARD) at 3.1%, Aclaris Therapeutics, Inc. (ACRS) at 2.9%, Upstream Bio, Inc. (UPB) at 2.6% of the reported portfolio.
Decheng Capital LLC reported a 13F portfolio worth $731.75M across 14 positions for Q2 2026. That is up 10.7% from the previous quarter.
Its largest purchases by value were Tango Therapeutics, Inc. ($625.20K). It opened 1 new positions.
Its largest sales by value were Revolution Medicines, Inc. ($7.65M), NewAmsterdam Pharma Co N.V. ($5.02M), Krystal Biotech, Inc. ($1.89M). It exited 1 positions entirely.
From the Form 13F-HR reports Decheng Capital LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.